Intrexon: Energy Segment Could Be Potential Blockbuster
Chris Bunge • 11 Comments
Chris Bunge • 11 Comments
Intrexon: Zika Virus Hype Is Nonsensical
Spotlight Research • 312 Comments
Spotlight Research • 312 Comments
Wed, Aug. 3, 11:42 AM
- Intrexon (XON +8.1%) pushes to session highs amid potential FDA approval for the use of genetically modified mosquitoes in the battle against the Zika virus in Florida.
- Oxitec, a U.K. subsidiary of the U.S. synthetic biology company, says it has been invited by Florida officials to propose a pilot study in the Florida Keys to evaluate the GM mosquito strain's effectiveness in reducing populations of Aedes mosquitoes, which can spread diseases including Zika, dengue, yellow fever and chikungunya.
- Oxitec says efficacy trials in Brazil, Panama, and the Cayman Islands showed that its GM mosquitoes can reduce localized Aedes aegypti populations by more than 90%.
- Florida health officials so far have confirmed 15 non-travel related cases of Zika.
Wed, Jun. 8, 9:09 AM
- Thinly traded nano cap Fibrocell Science (NASDAQ:FCSC) is down 47% premarket, albeit on only 3,800 shares, in response to its announcement that its Phase 2 clinical trial assessing lead product candidate azficel-T for the treatment of vocal cord scarring resulting in chronic/severe dysphonia (difficulty in speaking) failed to beat placebo. As a result, the company will cease development and focus its resources on gene therapy candidate FCX-007, being developed in collaboration with Intrexon (NYSE:XON).
- Azficel-T is a personalized gene therapy based on the patient's own cells called fibroblasts, the most common cell in the skin and connective tissue.
Fri, May 13, 9:28 AM
- Intrexon (NYSE:XON) slumps 6% premarket on increased volume in apparent response to bearish comments by TheStreet's Adam Feuerstein who questions the legitimacy of the company's technology and the lack of transparency from CEO R.J. Kirk. He says the dearth of claims credentialing the company's synthetic biology business reminds him of embattled blood testing firm Theranos.
Fri, May 13, 9:17 AM
Tue, May 10, 4:47 PM
- Intrexon (NYSE:XON) Q1 results ($M): Total Revenues: 43.4 (+28.3%); Operating Expenses: 84.0 (-30.6%); Net Loss: (64.4) (-337.6%); Loss Per Share: (0.55) (-320.0%). Consensus: Loss Per Share of $0.20 on revenues of $46.3M.
- EBITDA: (60.9) (-292.5); Non-GAAP EBITDA: 1.9 (+113.2%).
- Shares are down 2% after hours on light volume.
- Q2 Consensus: Loss Per Share of $0.15 on revenues of $56.3M.
Wed, Apr. 27, 3:40 PM
- Bears appear to be covering their short positions in Intrexon (XON +1.2%) after the remaining sections (2 - 8) of a bearish analysis by Spotlight Research were published earlier today on Seeking Alpha. Shares were down as much as 13% before recovering. No more smoking guns, apparently.
- Previously: Bearish SA article sinks Intrexon; shares off 26% (April 21)
Wed, Apr. 27, 9:11 AM
Mon, Apr. 25, 9:15 AM
- Thinly traded micro cap Fibrocell Science (NASDAQ:FCSC) is up 7% premarket on light volume in response to its announcement that the FDA has designated gene therapy FCX-013 an Orphan Drug for the treatment of localized scleroderma, a chronic autoimmune disorder characterized by the painful and debilitating thickening of the skin and connective tissue.
- FCX-013, an autologous fibroblast cell designed to break down excess collagen at the site of disease, utilizes Intrexon's (NYSE:XON) gene regulation technology called RheoSwitch which offers transcriptional control of a range of therapeutic genes.
- Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
Thu, Apr. 21, 3:38 PM
- Intrexon (XON -25.5%) slumps on more than a 6x surge in volume in response an article published today on Seeking Alpha by Spotlight Research titled, "Intrexon: The Public Markets' Theranos Part 1 - Zika Virus Hype Is Nonsensical."
- The article, the first of eight planned, says the company's hype-fueled valuation, led by the Zika hysteria, is due for a major reset.
- Update: In a statement released this morning, April 22, Intrexon says the article, generated by an unnamed hedge fund seeking to discredit the company, is materially false and misleading and it intends to take appropriate steps to address the situation per advice from legal counsel.
Thu, Apr. 21, 12:48 PM
Wed, Apr. 13, 5:36 PM
Wed, Feb. 17, 10:07 AM
- Micro cap Inovio Pharmaceuticals (INO +4%) is up in early trading on increased volume in response to its announcement of positive preclinical data for its Zika virus vaccine candidate. In the study, DNA constructs, synthetically generated with the company's SynCon vaccine technology, targeting multiple Zika virus antigens and administered using its CELLECTRA electroporation delivery technology induced robust and durable immune responses. Phase 1 testing is expected to commence before year end.
- Investors seeking to profit from a Zika-stoked up move need to be patient. Regulatory clearance for a vaccine, even with accelerated review, is probably two years away. Drugs to treat infection are further away still.
- Intrexon (XON +6.4%) has seen some recent bullish action (shares doubled from mid-January to early February) in apparent anticipation of the revenue potential of its genetically modified sterile male mosquitoes, OX513A, that produced a 95% reduction in the Aedes aegypti population, the type of mosquito that transmits Zika and Dengue, in a small study in northeast Brazil. Here, again, sobriety is key. The beneficial effects are only temporary (unless the sterile guys are repeatedly released over a wide area, a tall order since mosquitoes only travel ~200 yards so covering a large area would require substantial human and physical resources). Intrexon's pricing leverage will also be constrained because irradiated sterile mosquitoes perform just as effectively and they will be available free-of-charge. Both techniques have similar cost structures, about $400/1M mosquitoes.
- Zika Index: (XON +6.4%)(INO +5.9%)(CERS +1%)(SNY +0.8%)(NLNK -1.8%)
Dec. 22, 2015, 9:16 AM
Oct. 21, 2015, 9:00 AM
- Micro cap Synthetic Biologics (NYSEMKT:SYN) is up 13% premarket on increased volume in response to its announcement that it has been awarded a $400K grant from the Bill and Melinda Gates Foundation to evaluate the potential of its monoclonal antibody, hu1B7, to prevent pertussis (whooping cough) in non-human primates and to provide support for its potential clinical application.
- The company is working with collaboration partner Intrexon (NYSE:XON) and researchers at UT Austin to develop SYN-005, a combination of two humanized antibodies, including hu1B7, for the treatment of critically ill infants with pertussis. SYN-005 is designed to neutralize the pertussis toxin and reverse the course of the disease.
- A preventive treatment for pertussis is a significant unmet medical need considering that 300K people die each each year from the condition, primarily infants in their first four months of life. Administration of hu1B7 at birth has the potential to protect infants for four months and save thousands of lives each year.
Oct. 14, 2015, 9:13 AM
Aug. 11, 2015, 9:16 AM
Intrexon Corp. is a biotechnology company focused on collaborating with companies in health, food, energy and the environment to create biologically based products. The company is engaged in the field of synthetic biology, which is an emerging discipline that applies engineering principles to... More
Industry: Medical Appliances & Equipment
Country: United States